SCHEMBL6316010

SCHEMBL6316010

Cc1[nH]c2ccc(OCCN3CCC(c4ccccc4)C3)cc2c1C(=O)OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.48
MAPKAPK2 P49137 1/20 0.45
MAOB P27338 4/20 0.45
MAOA P21397 2/20 0.45
KDM4E B2RXH2 2/20 0.44
BCHE P06276 1/20 0.44
ACHE P22303 1/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
HSD17B10 Q99714 1/20 0.43
LTA4H P09960 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6316093 0.99 PARP1 (0.47) PARP1MAPKAPK2MAOBMAOAKDM4E
SCHEMBL6317111 0.91 KDM4E (0.52) MAOBMAOAKDM4EBCHEACHE
SCHEMBL6316336 0.89 LTA4H (0.48) MAOBMAOAKDM4EBCHEACHE
SCHEMBL6318493 0.89 LTA4H (0.48) MAOBMAOAKDM4EBCHEACHE
SCHEMBL6322012 0.89 LTA4H (0.48) MAOBMAOAKDM4EBCHEACHE
SCHEMBL6314840 0.89 KDM4E (0.48) MAOBMAOAKDM4EBCHEACHE
SCHEMBL6323073 0.89 KDM4E (0.43) MAOBMAOAKDM4EBCHEACHE
SCHEMBL6316855 0.87 HTT (0.53) KDM4ELMNAMAPTHPGDHTT
SCHEMBL6320566 0.86 MAOB (0.41) MAPKAPK2MAOBMAOAKDM4EBCHE
SCHEMBL6323166 0.86 KDM4E (0.48) MAOBMAOAKDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-04-07 US claimed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US claimed
US-6951848-B2 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC., (US) 2005-10-04 US disclosed
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2005-04-07 US disclosed
EP-1377549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR Millennium Pharmaceuticals, Inc. (US) 2004-01-07 EP disclosed
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. 2003-04-03 US disclosed
WO-2002072549-A1 FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR MILLENNIUM PHARMACEUTICALS, INC. (US) 2002-09-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064991-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 PARP1 3510/4885MAPKAPK2 1129/4885MAOB 3386/4885
US-20050075348-A1 Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor ACKR3, CCR5, CXCR4 PARP1 3493/4885MAPKAPK2 1058/4885MAOB 3124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.